title: Hypomethylating agents and chemotherapy in MDS.
abstract: Until recently, the treatment of higher risk myelodysplastic syndrome was based on [1] Intensive chemotherapy using anthracycline-AraC combinations, leading to a lower complete remission rates and a shorter CR duration compared with de novo AML [2], low dose chemotherapy with limited CR rate mainly restricted to patients with normal karyotype. Azacitidine was the first drug to significantly improve survival in higher risk MDS, although it is not curative. Thus, the survival improvement obtained with azacitidine must be the starting point for combination studies, and for utilization of this drug in other situations (before allo SCT, or after chemotherapy or allo SCT as maintenance treatment).
authors: Service d'hématologie clinique, Hopital Avicenne (AP-HP), 125, rue de Stalingrad, 93009 Bobigny, France. Electronic address: lionel.ades@sls.aphp.fr.
authors: Lionel
authors: L
authors: Adès
authors: Hematology, AOU Careggi, University of Florence, Largo Brambilla 3, Florence, Italy.
authors: Valeria
authors: V
authors: Santini
mesh_terms: D064591:Allografts; D018943:Anthracyclines / Q000627:therapeutic use*; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D003561:Cytarabine / Q000627:therapeutic use*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000473:pathology; D009190:Myelodysplastic Syndromes / Q000473:pathology / Q000628:therapy*; D033581:Stem Cell Transplantation
chemical_list: D018943:Anthracyclines; D000964:Antimetabolites, Antineoplastic; D003561:Cytarabine
keywords: azacitidine; chemotherapy; decitabine; hypomethylating agents